ARTICLE SUMMARY:
The recent FDA approval of Abbott Vascular’s Absorb Bioresorbable Vascular Scaffold ushers in the first potentially game-changing technology the US coronary stenting field has seen since drug-eluting stents were introduced more than a decade ago. But exactly how much traction will this device get in the marketplace?
Abbott Vascular Inc. achieved a long-awaited goal in early July when FDA issued final PMA approval for its Absorb GT1 BVS (Bioresorbable Vascular Scaffold), the first fully resorbable drug-eluting coronary stent to reach the US market.
